#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Programs for prevention of osteoporotic fractures in the Czech Republic


Authors: Jaroslav Duba 8;  MUDr. Richard Pikner, Ph.D. 1,2,3;  Pavel Němec 4,5;  Vladimír Palička 6;  Martin Švagr 7;  Karel Hejduk 4,5;  Barbora Budíková 4;  Ondřej Ngo 4,5;  Jiří Jarkovský 4,5;  Ondřej Májek 4,5;  Jan Vachek 9;  Miroslava Aszalayová 10;  Petr Kasalický 11;  Lukáš Dušek 8
Authors‘ workplace: Oddělení klinických laboratoří a kostního metabolismu, Klatovská nemocnice a. s. 1;  Ústav klinické biochemie a hematologie, Lékařská fakulta v Plzni, Univerzita Karlova v Praze 2;  Katedra záchranářství, diagnostických oborů a veřejného zdravotnictví, Fakulta zdravotnických studií, Západočeská Univerzita v Plzni 3;  Ústav zdravotnických informací a statistiky České republiky, Národní screeningové centrum, Praha 4;  Institut biostatistiky a analýz, Lékařská fakulta, Masarykova univerzita, Brno 5;  Osteocentrum, ÚKBD, LF UK a FN v Hradci Králové 6;  Ortopedické oddělení, Klatovská nemocnice a. s. 7;  OAKS Consulting s. r. o., Praha 8;  Interní oddělení, Klatovská nemocnice a. s. 9;  InterMedic Praha s. r. o. 10;  Affidea Praha s. r. o. 11
Published in: Geriatrie a Gerontologie 2022, 11, č. 1: 25-35
Category: Review Article

Overview

Every third female and every fifth male over 50 years of age suffer from an osteoporotic fracture. Approximately 15,000 patients with hip fractures in the Czech Republic are hospitalized every year, and nearly one-fifth of them die within one year of the complications associated with this injury. Additionally, initial osteoporotic fracture increases the risk of another subsequent fracture by 2–5 fold. Under-diagnosis of osteoporosis in the population is one of the most severe problems in the Czech Republic, which is related not only to the lack of information about the problem itself in the target population but also to the absence of comprehensive programs of prevention of osteoporotic fractures.

Two projects launched in 2021 aim to improve this situation. The first is a national, prospective, multicentre pilot project entitled „OSTEO“ focused on secondary prevention of osteoporotic fractures in persons over 50 who have had their first osteoporotic fracture. The second is the primary and secondary prevention project, named “Q-OSTEOPOROSIS“.

The global objective of the pilot project is to verify the feasibility of implementing the FLS system in the Czech healthcare environment and to design a population-wide programme for the prevention of secondary osteoporotic fractures in the Czech Republic based on this approach to ensure maximum positive impact on population health and high cost-effectiveness of the intervention.

Key objective of the “Q-OSTEOPOROSIS“ is to provide comprehensive care for patients at risk of potential osteoporotic fractures according to guidelines and evidence based medicine, which will be predictable for the health system in terms of benefits, costs and long-term financial sustainability and will bring a significant reduction in the incidence of osteoporotic fractures in the long term horizon.

Given that geriatricians have a significant group of patients in their care who already have a confirmed or increased risk of osteoporosis, CGGS has initiated negotiations in the above-mentioned quality care programs to involve geriatricians in the process of these important changes. CGGS will keep you informed of the progress and results of the negotiations.

Keywords:

prevention – DXA – fracture – FRAX – osteoporosis – healthcare quality – fracture liaison service – FLS


Sources

1. Kanis JA, Johansson H, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24: 23–57.

2. Pikner R, Palička V, Vyskocil V, et al. Definice osteoporotické (křehké) zlomeniny: stanovisko Společnosti pro metabolická onemocnění skeletu České lékařské společnosti J. E. Purkyně. Clin Osteol 2020; 25: 83–84.

3. Svedbom A, Hernlund E, Ivergård M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8: 137.

4. Stepan J, Vaculik J, Pavelka K, et al. Hip Fracture Incidence from 1981 to 2009 in the Czech Republic as a Basis of the Country-Specific FRAX Model. Calcif Tissue Int 2012; 90: 365–372.

5. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375–382.

6. Edwards BJ, Bunta AD, Simonelli C, et al. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res 2007; 461: 226–230.

7. Boonen S, Autier P, Barette M, et al. Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int 2004; 15: 87–94.

8. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30: 3–44.

9. Bessette L, Ste-Marie LG, Jean S, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008; 19: 79–86.

10. Borgström F, Karlsson L, Ortsäter G, et al. Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 2020; 15:

11. Štěpán J, Vaculik J, Palička V, et al. Péče o pacienty s nízkotraumatickou zlomeninou horního konce stehenní kosti. Následná osteologická péče. Doporučený postup České revmatologické společnosti, Společnosti pro metabolická onemocnění skeletu a České společnosti pro ortopedii a traumatologii. Česká revmatologie 2015; 23: 43–58.

12. Lukáš P, Švagr M, Pikner R. Fracture Liaison Service jako možný nástroj na zlepšení péče- zhodnocení zlomenin proximálního femuru a provedení denzitometrického vyšetření v letech 2012–2016 v Klatovské nemocnici a.s. Osteologický Bulletin 2017; 22: 109–112.

13. Black DM, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–1541.

14. Neer RM, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–1441.

15. Reginster J, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91.

16. Cummings SR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756–765.

17. McClung MR, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–340.

18. Harris ST, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–1352.

19. Reginster JY, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816–2822.

20. McLellan AR, Gallacher SJ, Fraser M. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 2003; 14: 1028– 1034.

21. McLellan AR, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 2011; 22: 2083–2098.

22. Marsh D, et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 2011; 22: 2051–2065.

23. Sander B, Elliot-Gibson V, Beaton DE, et al. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs. J Bone Joint Surg Am 2008; 90: 1197–1205.

24. Majumdar SR, et al. Osteoporosis case manager for patients with hip fractures: results of a cost- -effectiveness analysis conducted alongside a randomized trial. Arch Intern Med 2009; 169: 25– 31.

25. Chandran M, et al. Secondary prevention of osteoporotic fractures-an „OPTIMAL“ model of care from Singapore. Osteoporos Int 2013; 24: 2809–2817.

26. Wallace I, Callachand F, Elliott J, Gardiner P. An evaluation of an enhanced fracture liaison service as the optimal model for secondary prevention of osteoporosis. JRSM Short Rep 2011; 2: 8.

27. Chakravarthy J, Ali A, Iyengar Y, Porter K. Secondary prevention of fragility fractures by orthopaedic teams in the UK: a national survey. Int J Clin Pract 2008; 62: 382–387.

28. Murray AW, McQuillan C, Kennon B, Gallacher SJ. Osteoporosis risk assessment and treatment intervention after hip or shoulder fracture. A comparison of two centres in the United Kingdom. Injury 2005; 36: 1080–1084.

29. Mitchell P, et al. Implementation of Models of Care for secondary osteoporotic fracture prevention and orthogeriatric Models of Care for osteoporotic hip fracture. Best Pract Res Clin Rheumatol 2016; 30: 536–558.

30. Åkesson KE, McGuigan FEA. Closing the Osteoporosis Care Gap. Curr Osteoporos Rep 2021; 19: 58–65.

31. Duba J, Dušek L. Analýza dat ÚZIS 2010–2018. 2020. data on file.

32. Palička V, Rosa J, Býma S. Osteoporóza: Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. 2018. Dostupné z: https://smos.cz/ wp-content/uploads/2019/12/ dp_diagnosticke-a-terapeuticke-postupy-pro-praktiky-2018.pdf

Labels
Geriatrics General practitioner for adults Orthopaedic prosthetics
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#